The study is a Phase 3, multicenter, randomized,
double-blind, placebo-controlled trial to evaluate the safety and efficacy of S-217622 for the treatment of symptomatic nonhospitalized adults with high and low risk of progression to severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection.